Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation

Clinical Cancer Research

Volumn 14, Issue 10, 2008, Pages 2953-2961

  Willems, Amber J ^a   Dawson, Sarah Jane ^a   Samaratunga, Hema ^c   De Luca, Alessandro ^d   Antill, Yoland C ^a   Hopper, John L ^b   Thorne, Heather J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Department of Anatomical Pathology Sullivan Nicolaides Pathology ^*  (Australia)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; FAMILY STUDY; GENE LOCUS; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR SUPPRESSOR GENE; GENETICS; MIDDLE AGED; MOLECULAR GENETICS; MUTATION; NUCLEIC ACID AMPLIFICATION; NUCLEOTIDE SEQUENCE; PROSTATE TUMOR;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; GENES, BRCA1; GENES, BRCA2; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PROSTATIC NEOPLASMS;

EID: 49649115901     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5237     Document Type: Article

References (45)

1. Cancer in Australia 2001. Australian Institute of Health and Welfare (AIHW) & Australasian Association of Cancer Registries (AACR). 2004.
2. Hunter DJ, Riboli E, Haiman CA, et al. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer 2005;5:977-85.
3. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91:1310-6.
4. Agalliu I, Kwon EM, Zadory D, et al. Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer. Hum Cancer Biol 2007;13:839-43.
5. Edwards SM, Kote-Jarai Z, Meitz J, et al. Two percent of men with early-onset prostate cancer harbor germ-line mutation in the BRCA2 gene. Am J Hum Genet 2003;72:1-12.
6. Hopper JL, Bishop DT, Easton DF. Population-based family studies in genetic epidemiology. Lancet 2005;366:1397-406.
7. Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-3.
8. Collins N, McManus R, Wooster R, et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 1995;10:1673-5.
9. Gudmundsson J, Johannesdottir G, Bergthorsson JT, et al. Different tumour types from BRCA2 carriers show wild-type chromosome deletions on 13q12-13. Cancer Res 1995;55:4830-2.
10. Armes JE, Trute L, White D, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 1999;59:2011-7.
11. Osorio A, de la Hoya M, Rodriguez-Lopez R, et al. Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int J Cancer 2002;99:305-9.
12. Esteller M, Fraga MF, Guo M, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001;10:3001-7.
13. Honrado E, Benitez J, Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol 2005;18:1305-20.
14. Chan KY, Ozcelik H, Cheung AN, Ngan HY, Khoo US. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res 2002;62:4151-6.
15. Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B, Buller RE. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002;94:1396-406.
16. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
17. Gronberg H, Ahman A-K, Emanuelsson M, Bergh A, Damber J-E, Borg A. BRCA2 mutation in a family with hereditary prostate cancer. Genes Chromosomes Cancer 2001;30:299-301.
18. Li C, Larsson C, Futreal A, et al. Identification of two distinct deleted regions on chromosome 13 in prostate cancer. Oncogene 1998;16:481-7.
19. Bane AL, Beck JC, Bleiweiss I, et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 2007;31:121-8.
20. Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006;49:22-34.
21. Mann GJ, Thorne H, Balleine RL, et al. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 2006;8:R12.
22. John EM, Hopper JL, Beck JC, et al. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 2004;6:R375-89.
23. Wu L, Patten N, Yamashiro CT, et al. Extraction and amplification of DNA from formalin-fixed, parraffinembedded tissues. Appl Immunohistochem Mol Morphol 2002;10:269-74.
24. Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002;30:e57.
25. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
26. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000;92:564-9.
27. AJCC Cancer Staging Manual. American Joint Committee on Cancer: Prostate (AJCC). 6th ed.2002.
28. Edwards SM, Dunsmuir WD, Gillett CE, et al. Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer. Int J Cancer 1998;78:1-7.
29. Melamed J, Einhorn JM, Ittmann MM. Allelic loss on chromosome 13q in human prostate carcinoma. Clin Cancer Res 1997;3:1867-72.
30. Hyytinen E-R, Frierson HFJ, Boyd JC, Chung LWK, Dong J-T. Three distinct regions of allelic loss at 13q14, 13q21 -22 and 13q33 in prostate cancer. Genes Chromosomes Cancer 1999;25:108-14.
31. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
32. King TA, LiW, Brogi E, et al. Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann Surg Oncol 2007;14:2510-8.
33. Cook WD, McCaw BJ. Accommodating haploinsufficient tumor suppressor genes in Knudson's model. Oncogene 2000;19:3434-8.
34. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 2005;42:711-9.
35. Tulinius H, Olafsdottir GH, Sigvaldason H, et al. The effect of a single BRCA2 mutation on cancer in Iceland. J Med Genet 2002;39:457-62.
36. Sigurdsson S, Thorlacius S, Tomasson J, et al. BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med 1997;75:758-61.
37. Tryggvadottir L, Vidarsdottir L, Thorgeirsson T, et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 2007;99:929-35.
38. Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 2004;91:1580-90.
39. Antoniou AC, Cunningham A, Peto J, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancer: updates and extensions. Br J Cancer 2008, March 15 [Epub ahead of print].
40. Agalliu I, Karlins E, Kwon EM, et al. Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. Br J Cancer 2007;97:826-31.
41. Gayther SA, de Foy KA, Harrington P, et al.; The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. Cancer Res 2000;60:4513-8.
42. Mitra A, Fisher C, Foster CS, et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 2008;98:502-7.
43. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94:1358-65.
44. Lalloo F, Varley J, Ellis D, et al. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 2003;361:1101-2.
45. Mitra AV, Bancroft EK, Eeles RA. A review of targeted screening for prostate cancer: introducing the IMPACT Study. BJU Int 2007;99:1350-5.